Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$12.86 USD
+1.88 (17.12%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $12.85 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 21 - 40 ( 136 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Continues To Make Progress As TVTX Preannounces Beat
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 HARMONY Study of Pegtibatinase to Support First Potential Disease-Modifying Therapy For HCU; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Filing Planned in 1Q24 For FILSPARI''s Full Approval in IgAN; Reorganization Extends Cash Runway to 2028; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IgAN sNDA Advances, FSGS No Go While Workforce Reduction Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TVTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Fizzled A Bit in 3Q23, But Continue To Receive Positive Doc Feedback
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney KOL Check: Traversing Through The PROTECT Data [Call Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney KOL Check - Traversing Through The TVTX PROTECT Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Narrow Miss on Confirmatory eGFR Total Slope Endpoint Complicates Path to Full Approval for FILSPARI; Cut PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PROTECT Readout Mixed, But Stock Reaction Appears Overdone
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: FILSPARI to Accelerate in 2H; Topline eGFR Data by Early 4Q; HCU Phase 3 by YE23; Trim PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Launch Gets More Interesting As We Go; PROTECT Pulls Forward
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving On With MIRM -- TVTX Divests Bile Acid Franchise
Provider: Wedbush Securities Inc.
Analyst: CHICO L